• Image 01
  • Image 02
  • Image 03
  • Image 04
  • Image 05
  • Image 06
Need assistance? Contact Us: 1-800-255-5897

Menu

  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
  • Home
  • About Us
    • Company Overview
    • Management Team
    • Board of Directors
  • Your Loan Service Center
  • MAKE A PAYMENT
  • Business Service Center
  • Contact Us
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Takeda Pharmaceutical Company Limited American Depositary Shares (each (NY:TAK)

13.72 +0.12 (+0.88%)
Official Closing Price Updated: 7:00 PM EDT, Jul 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Takeda Pharmaceutical Company Limited American Depositary Shares (each

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales
July 30, 2025
Takeda reported a 30% rise in Q1 profit and beat EPS estimates, offsetting Vyvanse losses with growth in oncology, plasma, and rare disease drugs. 
Via Benzinga
Earnings Scheduled For July 30, 2025
July 30, 2025
 
Via Benzinga
Insights Ahead: Takeda Pharmaceutical's Quarterly Earnings
July 29, 2025
 
Via Benzinga
Alkermes Offers The Next Proof Point For Its Narcolepsy Approach. Stock Dives.
July 21, 2025
All four companies are testing out orexin agonists to improve the symptoms of narcolpesy. 
Via Investor's Business Daily
S&P 500, Dow Jones Pharma Stocks Boomerang As Trump Threatens Drug-Price Reform
May 12, 2025
It's still unclear how President Donald Trump plans to tie drug prices in the U.S. to international prices. 
Via Investor's Business Daily
Topics Government Stocks
Earnings Scheduled For May 8, 2025
May 08, 2025
 
Via Benzinga
Preview: Takeda Pharmaceutical's Earnings
October 30, 2024
 
Via Benzinga
Japanese Pharma Company Takeda Expects Limited Exposure To US-China Tariffs
May 08, 2025
Takeda reported a 25% drop in FY2024 net profit but saw revenue and operating profit growth. 
Via Benzinga
UK's Health Agency Endorses Pfizer's Blood Cancer Combo Therapy As First For Untreated Hodgkin Lymphoma Patients
April 02, 2025
NICE recommended Pfizer's Adcetris for NHS use in advanced Hodgkin lymphoma, citing strong trial data and a new discount agreement with Takeda. 
Via Benzinga
Chinese Biotech Ascentage Pharma's Valuation Driven By Late-Stage De-Risked Assets: JPMorgan
March 27, 2025
JP Morgan sees strong growth for Ascentage Pharma, citing its late-stage cancer drugs. The biotech's 2024 sales surged 342% YoY, driven by a Takeda payment. 
Via Benzinga
Pharmaceutical Firms Say UK Investment Is 'Unlikely' Unless Payment Levy Is Adressed
March 21, 2025
UK pharma leaders warn excessive NHS levies threaten industry growth, urging the government to reform payments. The ABPI highlights declining UK R&D investment and falling global competitiveness. 
Via Benzinga
Takeda-Protagonist Therapeutics Partnered Investigational Drug Hits Primary Goal In Late-Stage Study In Patients With Type Of Blood Cancer
March 03, 2025
Rusfertide met all primary and secondary endpoints in a Phase 3 trial for polycythemia vera, with strong efficacy and safety results, earning Protagonist $25 million. 
Via Benzinga
Neurocrine Obtains Exclusive Rights For Depression Drug, Takeda Reacquires Japan Rights
January 28, 2025
Neurocrine Biosciences advances Phase 3 plans for osavampator after achieving Phase 2 success in major depressive disorder, amending its Takeda deal. 
Via Benzinga
FDA Bans Red Dye No. 3 Effective January 2027, Cites Cancer Risks: Food Stocks To Watch
January 15, 2025
The U.S. Food and Drug Administration announced a ban on Red No. 3, an artificial food coloring linked to cancer in animal studies, effective Jan. 15, 2027. 
Via Benzinga
Takeda's HYQVIA Approved in Japan To Treat Immunodeficiency
December 27, 2024
Takeda's HYQVIA receives approval in Japan for treating immunodeficiencies, offering a more convenient, less frequent subcutaneous infusion option. 
Via Benzinga
Teva Pharmaceutical Releases Impressive Phase 2 Candidate Data For Gastro-Related Diseases
December 18, 2024
Teva and Sanofi report positive Phase 2b data for duvakitug, showing significant remission in UC and CD patients, boosting analyst confidence and price targets. 
Via Benzinga
Earnings Scheduled For January 30, 2025
January 30, 2025
 
Via Benzinga
Keros Therapeutics' Licensing Deal With Takeda Aligns With Broader Opportunity For Elritercept: Analyst
December 03, 2024
Takeda inks a licensing deal with Keros for elritercept, a late-stage anemia drug, and plans a Phase 3 trial in myelodysplastic syndromes. 
Via Benzinga
AC Immune's Active Immunotherapy Shows Antibody Responses In Early Parkinson's Patients
November 14, 2024
AC Immune reports interim results from Phase 2 trial of ACI-7104.056 active immunotherapy for early Parkinson's disease. 
Via Benzinga
Urgency, Debate Mark COP29 As Leaders Push For Carbon Market Rules, Worry About Trump
November 12, 2024
Global leaders gather at COP29 to address climate change, carbon market mechanisms, and climate finance. Urgency and controversy at a fossil fuel reliant host country, but focus on establishing rules... 
Via Benzinga
Topics Climate Change
Alumis' Investigational Lead Candidate Supports Superior Profile Than Bristol Myers' Commercialized Drug, Analyst Sees 170% Stock Upside
October 17, 2024
HC Wainwright has initiated coverage on Alumis, highlighting the biopharmaceutical company's lead drug candidate, ESK-001. The analyst notes ESK-001's superior clinical data compared to Bristol Myers... 
Via Benzinga
Johnson & Johnson Ends Phase 2 Study For Dengue Antiviral Amid R&D Reprioritization
October 04, 2024
Johnson & Johnson has discontinued its Phase 2 study of mosnodenvir, an investigational antiviral candidate for dengue prevention, as part of a strategic shift in its R&D portfolio. Final efficacy data... 
Via Benzinga
Protagonist Therapeutics' Two Investigational Candidates Target Over $10B Market, Bullish Analyst Opines
September 10, 2024
Truist Securities has initiated coverage on Protagonist Therapeutics, praising its first-in-class lead asset with promising Phase 2 data in rare blood cancer and a multi-billion dollar potential. 
Via Benzinga
Enliven Therapeutics' Leukemia Candidate Could Challenge Pfizer, AstraZeneca In Broader Target Market: Analyst
September 09, 2024
HC Wainwright initiated coverage on Enliven Therapeutics, noting its innovative small molecules for tumor treatments. HC Wainwright gave a Buy rating with a $37 price target, projecting significant... 
Via Benzinga
Shortage Relief: More Takeda's Vyvanse For ADHD On the Way As US Ramps Up Production
September 06, 2024
Increase in production of Takeda's ADHD drug Vyvanse, approved by DEA to address ongoing shortages both domestically and globally. 
Via Benzinga
Ascendis' Hypoparathyroidism Drug Scores FDA Approval As First and Only Treatment, Replacing Takeda's Drug Discontinued Due To Supply Issues
August 12, 2024
FDA grants approval to Ascendis Pharma's Yorvipath (TransCon PTH) for adult hypoparathyroidism. Yorvipath offers continuous parathyroid hormone exposure and is set to launch in the U.S. with patient... 
Via Benzinga
Why Is Japanese Drugmaker Takeda Pharmaceutical Stock Trading Higher On Wednesday?
August 07, 2024
Takeda Pharmaceutical stock rises following European Commission approval of Adzynma for treating ADAMTS13 deficiency in cTTP patients. Adzynma is the first enzyme replacement therapy in the EU for this... 
Via Benzinga
TAK Stock Earnings: Takeda Pharmaceutical Reported Results for Q1 2024
July 31, 2024
Takeda Pharmaceutical just reported results for the first quarter of 2024. 
Via InvestorPlace
3 Biotech Stocks to Buy on the Dip: July 2024
July 29, 2024
Biotech stocks are critically important to the broader market. However, it might make more sense to consider buying on the dip. 
Via InvestorPlace
Newly-Listed Psoriasis-Focused Alumis Attracts Analysts' Attention With Promising Lead Program And Modest Valuation
July 24, 2024
Guggenheim Partners initiated coverage on Alumis, highlighting its lead asset ESK-001, a TYK2 inhibitor for plaque psoriasis and systemic lupus erythematosus. With upcoming Phase 3 trials and no JAK... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Site Logo
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Having difficulty making your payments? We're here to help! Call 1-800-255-5897

Copyright © 2019 Franklin Credit Management Corporation
All Rights Reserved
Contact Us | Privacy Policy | Terms of Use | Sitemap